The diagnostics manufacturer experienced strong growth in 2023 with increasing global reach of its innovative tests & technologies, available in 80+ countries.
There is increasing demand for molecular diagnostic tests and technologies due to the rise in genetic diseases and the desire for personalized medicine. In the field of allergy diagnostics, we offer the most future-oriented test on the market, as our technology allows us to deliver much more precise and meaningful results and act accordingly. In the long term, our test will provide lasting relief for the healthcare system.
Dr. Christian Harwanegg, CEO von MADx
Vienna (OTS) – Particularly high-growth markets were Germany, where MADx was able to double sales in 2023, as well as Italy, Spain and Poland. MADx has set itself the goal of revolutionizing immunodiagnostics with its state-of-the-art allergy test and the associated evaluation and analysis software. Further market entries are planned for 2024.
Molecular diagnostics is a rapidly growing market, valued at $14.9 billion worldwide in 2022 and will reach over $47 billion by 2032 according to the latest forecasts. This growth is shaped by various factors.
Dr. Christian Harwanegg, CEO of MADx explains: “There is increasing demand for molecular diagnostic tests and technologies due to the rise in genetic diseases and the desire for personalized medicine. In the field of allergy diagnostics, we offer the most future-oriented test on the market, as our technology allows us to deliver much more precise and meaningful results and act accordingly. In the long term, our test will provide lasting relief for the healthcare system.”
MADx’s molecular allergy test (ALEX²) is the leading blood test in its category and is characterized by the largest range of allergens tested (up to 300), thereby providing a comprehensive picture of the sensitization status of patients. MADx has set a remarkable benchmark in allergy diagnostics by providing more molecular test results than the entire industry combined. This remarkable achievement not only underlines MADx’s commitment to excellence and innovation in diagnostics, but also sets new standards for quality and efficiency in molecular testing. The results provide doctors with additional valuable information about possible cross-reactions and individually suitable therapy options.
Find out more about the MADx allergy test
The Allergy Xplorer (ALEX²) tests 295 allergy triggers in one step
Questions & Contact:
Mag. Barbara Hamza
Teamlead Marketing & Communications
Macro Array Diagnostics GmbH
Lemböckgasse 59/Top 4
A-1230, Vienna
Tel.: +43 (0) 664 3981134
Email: hamza@macroarraydx.com